RSSL responds to change in Good Distribution Practice guidelines

Published: 3-Apr-2013
Training & Education Regulatory Logistics

Extra dates for courses covering the changes for distributors wishing to ensure their licence meets the new requirements


The new 'Commission Guidelines on Good Distribution Practice (GDP) of Medicinal Products for Human Use' introduce massive changes in the expectations on companies involved in distributing pharmaceutical products. The new guidelines have radically altered the working landscape for wholesale distributors, freight forwarders, agents and brokers, and everyone else involved in the distribution of pharmaceutical products.

Distributors that wish to ensure that their licence meets the new requirements, will have a lot to do to make sure they meet the standards that the industry is trying to set.

RSSL ran its first course covering the changes in the GDP guidelines just a day after they were published last month. Extra dates for courses covering these important changes have been set for 9 April, 21 May and 13 June.

  • Companies:
  • Reading Scientific Services Ltd
See more

You may also like

Training & Education

RSSL announces new Innovation Hub to support biotech companies

Read more
The hub has a dedicated laboratory space and flexible support services for smaller biotech organisations to accelerate product development

Trending Articles

  1. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  2. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Training & Education

RSSL announces new Innovation Hub to support biotech companies

The hub has a dedicated laboratory space and flexible support services for smaller biotech organisations to accelerate product development
Training & Education

RSSL announces new state-of-the-art facility

Opening as part of ambitious expansion plan ew facility will increase capacity to aid RSSL in meeting the growing demand of its global client base
Regulatory

RSSL wins Employer of the Year Award

RSSL was crowned Employer of the Year in recognition of its outstanding dedication to staff development, engagement and wellbeing
Regulatory

RSSL Wins Business of the Year Award

The judges praised its forward-thinking approach and strong commercial performance
Training & Education

RSSL QP training - achieve your QP ambitions

Starting your QP journey with RSSL
Regulatory

Ethypharm and RSSL partnership fast-tracks priority medicine

Ethypharm has collaborated with RSSL to accelerate the manufacture and batch release of fentanyl injection
Regulatory

Adequately establishing contamination risk in drug products

Recent changes within the United States Pharmacopoeia (USP) and European Pharmacopoeia (EP) put emphasis on risk assessment for the likelihood of contamination as opposed to enforcing mandatory testing in drug products, Alan Cross, technical specialist, metals laboratory at RSSL, explains
Subscribe now